Get in touch.

List of contacts

Do you have any questions about ZB MED`s services or the range of literature we offer? Or maybe you need some tips on how to run searches in LIVIVO?

Contact

info@zbmed.de
Phone: +49 (0)221 999 892 240

Cologne Site

Medicine and Health

Address:
ZB MED – Information Centre for Life Sciences
Gleueler Straße 60
50931 Cologne (Köln)
Germany

Bonn Site

Nutritional, Environmental and Agricultural Sciences

Address:
ZB MED – Information Centre for Life Sciences
Friedrich-Hirzebruch-Allee 4
53115 Bonn
Germany

InfoCenter

INFORMATION.

KNOWLEDGE.
LIFE.

An infrastructure and research centre for data and information in the life sciences.

Studying or working in life sciences?

We've got the research tools you need.

Conference detail

Conference details

15.10.2019 - 16.10.2019

SMi’s 9th Annual Orphan Drugs & Rare Diseases Conference

Location
London
Contact

Organiser Name SMi Group

Contact: Simi Sapal

ssapal@smi-online.co.uk

02078276000

Country
United Kingdom
Subject area(s)
Shortinfo

SMi Group are proud to announce the 9th Annual Orphan Drugs and Rare Diseases Conference, taking place on the 15th and 16th October 2019 in London, UK.

The orphan drug market is continuously growing and is expected to reach $176 billion by 2020, with a CGR of 10.5% just for orphan drugs – this is twice the growth rate of the overall prescription drug market (5.3% CGR from 2014-2020). By 2020, orphan drugs are set to account for 19% of global prescription sales.

This is due to the arising interest from pharmaceutical companies for underlying benefits, such as the potential discovery of mechanisms for more common diseases, and also the involvement of many smaller biotechnology start-up companies who are primarily focused on rare diseases.


The 2019 agenda features various key presentations by leading solution providers, biotechnology companies, clinical researchers, regulatory professionals and charity leaders discussing possible ways to accelerate orphan drug development and access to rare disease patients, including the introduction of recent technologies and products to help aid the access of orphan drugs.